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Pseudomonas aeruginosa remains one of the most impor-
tant pathogens in the nosocomial setting [1]. P. aeruginosa
exhibits intrinsic resistance to several antimicrobial agents.
The antipseudomonal β-lactams represent a major weapon
against Pseudomonas infections, either for monotherapy or
for combination therapy, for which β-lactams almost
invariably represent one of the components. Therefore,
resistance to these agents constitutes a major challenge for
anti-Pseudomonas chemotherapy. Several mechanisms can
contribute to β-lactam resistance in P. aeruginosa, includ-
ing β-lactamase production, outer membrane impermeabil-
ity and active efflux mediated by RND-type efflux systems
[1]. During the last decade, the metallo-β-lactamases
(MBLs) have emerged as new threatening mechanisms of
broad-spectrum β-lactam resistance in P. aeruginosa. In
fact, these enzymes can efficiently degrade virtually all
antipseudomonal β-lactams (except aztreonam), while they
are not susceptible to therapeutic β-lactamases inhibitors
[2]. Based on amino acid sequence homology, these MBLs
have been classified into four major types: IMP, VIM, SPM
and GIM. Clinical isolates harbouring the MBLs IMP and
VIM have been increasingly reported worldwide, mostly in
European and Asian countries [2]. This increase in
occurrence, types and rate of dissemination of MBLs
makes early detection very critical. The benefits of such
treatment include the timely implementation of strict
infection control practices, as well as clinical guidance.
The aim of this study was to determine the presence of
these enzymes in imipenem-resistant P. aeruginosa isolates
collected at the Centro Hospitalar of Coimbra (CHC),
during a two-year period (April 2003 to April 2005) and to
ascertain their clonal relationship. CHC is a cluster formed
by a central hospital and several specialised units located at
distances of less than 8 km, namely, Hospital dos Covões
(central hospital), Instituto Maternal (maternity hospital)
and Hospital Pediátrico (paediatric hospital). The Microbi-
ology Laboratory also analysed samples from another
hospital (Hospital de Pombal) located 30 km away.
Bacterial identification and minimal inhibitory concen-
trations (MIC) were performed with the MicroScan Walk-
Away (Dadebehring) system according to the instructions of
the manufacturer and API32GN or API PSE systems
(bioMérieux). All intermediate strains were considered as
nonsusceptible strains. The MICs of β-lactams were also
determined by E-test in isolates that presented the enzyme
VIM-2. The results were interpreted on the basis of CLSI
recommended breakpoints [3]. The screening of MBLs was
done by the double combined disk test [4]. Polymerase chain
reaction (PCR) analyses for the detection of MBLs genes
(blaIMP, blaVIM, blaGIM and blaSPM-1) were carried out for all
strains in which the screening test gave positive results [5].
The amplicons were directly sequenced on both DNA
strands on an ABI PRISM 377 automated sequencer. The
nucleotide and deduced amino acid sequences were analysed
with software available online (http://blast.ncbi.nlm.nih.gov/
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Blast.cgi). VIM-2-producing isolates were typed by random
amplified polymorphic DNA (RAPD) with primer 272 [5].
Samples with the same banding pattern were assigned a letter
indicating a single RAPD type. Those with no more than one
major band or three minor band differences were thought to
be related and great differences in the banding patterns were
considered to be a different pattern [5].
On the basis of resistance phenotype (resistance or
intermediate susceptibility to imipenem), 134 isolates were
selected and studied for MBL production. The susceptibil-
ity of these P. aeruginosa isolates relative to β-lactams
antibiotics was: ceftazidime, 56.7%; piperacillin plus
tazobactam, 47.4%, and aztreonam, 37.3%. Meropenem
still demonstrated some activity (20.3%). Among these
imipenem-resistant isolates, 3.7% were characterised by
multidrug resistance, including all of the tested drugs. In
our study, carbapenem resistance rates did not correlate
with the presence of VIM-2, as 80.6% of the strains were
resistant to imipenem without MBL production. This
demonstrates that other resistance mechanisms were in-
volved, such as permeability mutations via the loss of
porins or the up-regulation of efflux systems [1].
The combined disk method was positive in 40 imipenem-
resistant isolates, but by PCR, the presence of an amplicon
of 815 pb in size (detection of blaVIM) was observed in
only 26 isolates. No amplification was observed with
blaIMP, blaSPM and blaGIM primers. DNA sequencing of
the amplicons confirmed that these 26 isolates harboured
blaVIM-2. MBL-producing gram-negative organisms have
now been reported in many geographic regions [2]. The
MBL found in our hospital is VIM-2, which is scattered in
several European countries, namely, France, Italy and
Greece [2]. The blaVIM-positive isolates were detected
during the time of the study and appeared to be widely
distributed in the central hospital, and even outside of it.
blaVIM-positive P. aeruginosa represented 19.4% of the
carbapenem-resistant P. aeruginosa isolates. These numbers
are lower than those reported for MBL producers from a
SENTRY Antimicrobial Surveillance Programme [6], but
exceed other reports from Italy [7]. Among these isolates,
VIM-2 producers’ MICs were determined by E-test and the
results are presented in Table 1. Resistance to all of the
tested drugs was observed in 15.4% of these isolates.
Furthermore, the majority of the multidrug-resistant isolates
Table 1 Minimal inhibitory concentrations (MICs) of β-lactams of VIM-2-producing Pseudomonas aeruginosa and respective random amplified
polymorphic DNA (RAPD) types
Isolate no. MIC (mg/L) Ward/hospital RAPD type
IP MP CAZ AZT PIP
17735/03 >32 32 24 3 16 Neurosurgery/Hosp. Covões A
17872/03 >32 >32 24 3 8 Orthotraumatology/Hosp. Covões A
14593/03 >32 32 >256 16 >256 Reanimation/Hosp. Covões A
17000/03 >32 >32 32 3 24 Reanimation/Hosp. Covões A
19210/03 >32 >32 24 3 24 Reanimation/Hosp. Covões A
1891/04 >32 >32 2 3 24 Reanimation/Hosp. Covões A
12321/04 >32 >32 32 3 16 Reanimation/Hosp. Covões A
18441/03 >32 6 16 2 16 Medicine/Hosp. Covões A
712/04 >32 >32 24 3 16 Medicine/Hosp. Covões A
1825/04 >32 >32 32 256 32 Medicine/Hosp. Covões A
3647/04 >32 >32 32 2 16 Medicine/Hosp. Covões A
4584/04 >32 >32 32 2 24 Medicine/Hosp. Covões A
6741/04 >32 >32 24 16 24 Medicine/Hosp. Covões A
1801/04 >32 4 32 2 16 Pneumology/Hosp. Covões A
14349/04 >32 3 16 2 12 Pneumology/Hosp. Covões A
21800/04 >32 >32 32 4 16 Pneumology/Hosp. Covões A
429/05 >32 >32 32 6 32 Pneumology/Hosp. Covões A
17053/04 >32 8 32 1,5 32 Reanimation/Hosp. Covões A1
541/05 >32 >32 16 3 32 Pneumology/Hosp. Covões A1
15153/04 >32 >32 32 >256 >256 Medicine/Hosp. Pombal B
18769/04 >32 >32 24 64 >256 Medicine/Hosp. Pombal B
5783/03 >32 3 24 1 48 Infectious/Hosp. Covões C
11874/04 >32 >32 >256 96 >256 Infectious/Hosp. Covões D
17083/03 >32 >32 64 3 48 Infectious/Hosp. Covões D
7147/03 >32 4 2.5 3 4 Medicine/Hosp. Paediatric E
19168/03 >32 >32 64 2 16 UIC/Hosp. Paediatric F
IP=imipenem; MP=meropenem; CAZ=ceftazidime; AZT=aztreonam; PIP=piperacillin
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were producers of VIM-2, which agrees with other studies
carried out in Italy that described 76% VIM-2-producing P.
aeruginosa clinical isolates with resistant phenotype [8].
In this work, P. aeruginosa isolates that produce VIM-2
were detected in six different wards of Hospital dos Covões
and in another two geographically distinct hospitals
(Hospital Pediátrico and Hospital de Pombal). Six geno-
typically different strains were identified (Table 1). Pattern
A comprised 17 isolates (65.4%) that were disseminated in
five wards of the central hospital. Subpattern A1 was
constituted of two isolates closely related to pattern A,
suggesting that a small mutation occurred in isolate A,
creating the former pattern. These results demonstrated that
we had the same strain harbouring VIM-2 disseminated in
various wards of the central hospital. This reality was
different from another study carried out in Greece where the
VIM-2 isolates were unrelated [9]. Pattern B represented
two isolates of Hospital de Pombal, a geographically
distinct hospital. In the Infectious ward, two samples of
P. aeruginosa with identical patterns classified as D and
another isolate classified as pattern C were isolated. This
diversity suggested the spread of the blaVIM-2 gene among
genetically distinct P. aeruginosa strains [9, 10]. In this
ward, clone Awas not found, suggesting that the prevention
measures and control of the spread of pathogen are more
effective in this ward. The remaining two isolates were
identified as patterns E and F, respectively, and were
recovered from the Medicine ward and the Unit of Intensive
Care of Paediatric Hospital, another geographically distinct
hospital.
In our study, MBL-positive strains had a common
multidrug-resistant phenotype that not only included carba-
penems, but also last-generation cephalosporins, amino-
glycosides and fluoroquinolones. The possibility that
spreading transferable MBL genes among nosocomial
gram-negative pathogens could emerge as a major problem
in the clinical setting reinforces the need for the systematic
surveillance of these resistance determinants. The early
detection of MBL-carrying organisms is of paramount
clinical importance, as it allows the rapid initiation of strict
infection control practices, as well as the selection of
appropriate antimicrobial agents.
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